Stocks · News reference
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it will present two presentations at the upcoming ObesityWeek® 2026 Annual Meeting, taking place November 14-17,
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Amylyx Pharma (NASDAQ:AMLX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our
Filed: 2026-09-08 AccNo: 0001193125-26-385331 Size: 147 KB Item 1.01: Entry into a Material Definitive Agreement
Amylyx Pharmaceuticals has surged 247% in 2026 following positive Phase 3 trial results for avexitide, its experimental treatment for post-bariatric hypoglycemia. With no current FDA-approved treatments for PBH and potential peak sales of $1.5 billion, the stock shows promise but may have already priced in much of the upside. The analyst suggests waiting for a pullback to $28-$30 per share for a better entry point.